Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 43.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,994 shares of the biopharmaceutical company’s stock after purchasing an additional 1,523 shares during the period. Harvest Fund Management Co. Ltd’s holdings in Regeneron Pharmaceuticals were worth $5,251,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Quent Capital LLC grew its holdings in Regeneron Pharmaceuticals by 5.1% in the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 19 shares during the period. CreativeOne Wealth LLC purchased a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $200,000. Gamco Investors INC. ET AL acquired a new position in Regeneron Pharmaceuticals during the first quarter worth approximately $230,000. Gabelli Funds LLC raised its stake in Regeneron Pharmaceuticals by 3.0% during the first quarter. Gabelli Funds LLC now owns 1,859 shares of the biopharmaceutical company’s stock worth $1,789,000 after purchasing an additional 54 shares during the period. Finally, Kennedy Capital Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $5,210,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently commented on REGN shares. Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a report on Friday, November 1st. Barclays dropped their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Wells Fargo & Company cut their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, October 22nd. Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,099.55.

Insider Activity

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $738.00 on Monday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $735.95 and a fifty-two week high of $1,211.20. The business has a 50 day moving average price of $945.07 and a two-hundred day moving average price of $1,027.53. The firm has a market cap of $81.10 billion, a PE ratio of 18.26, a price-to-earnings-growth ratio of 2.84 and a beta of 0.15.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.